Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia Clinical Trial

Official title:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01879722
• Other study ID #: TAK-063_104
• Secondary ID: U1111-1139-5355
• Status: Completed
• Phase: Phase 1
• First received: June 13, 2013
• Last updated: August 11, 2014
• Start date: July 2013
• Est. completion date: June 2014

Study information

• Verified date: August 2014
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.

Description:

The drug being tested in this study is called TAK-063. TAK-063 is being tested to find a well-tolerated dose and also to treat schizophrenia. This study will look at how well different doses of TAK-063 are tolerated in healthy people of Japanese descent and in people with stable schizophrenia.

Three dose levels will be examined, starting at the lowest, in each population with 10 participants in each dose level. These participants will be randomized to receive TAK-063 (8 subjects) and placebo(2 subjects) QD for 7 days.

In total, approximately 60 participants will be enrolled in the study. This trial will be conducted in single site in the United States. The overall time to participate in this study is up to 42 days. Participants will make 2 visits to the clinic, including 8-10 days confinement to the clinic, and will be contacted by telephone 7 days after last dose of study drug for a follow-up assessment.

Dose escalation and the actual choice of the subsequent dose level will only occur following a review of the blinded data from the previous cohorts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 77
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Healthy Participants:

1. Aged 20-55 years, inclusive, at the time of informed consent and first study medication dose.

2. Is a healthy adult male or female of Japanese descent (born to Japanese parents and grandparents and has lived outside of Japan for less than 5 years).

3. Weighs at least 45 kg and has a body mass index (BMI) between 18.0 and 28.0 kg/m^2, inclusive, at Screening.

Participants with Stable Schizophrenia:

1. Is aged 18 to 55 years, inclusive, at the time of informed consent and first study medication dose.

2. Is an adult male or female with a diagnosis of schizophrenia or schizoaffective disorder.

3. Weighs at least 45 kg and has a BMI between 18.0 and 35.0 kg/m^2, inclusive at Screening.

4. Has been receiving a stable dose of antipsychotic monotherapy for at least 1 month prior to Screening.

5. Has not had an acute exacerbation of psychosis or been hospitalization for the treatment of schizophrenia or schizoaffective disorder for at least 3 months prior to Screening.

Exclusion Criteria:

All Participants:

1. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality (other than the disease being studied), which may impact the ability of the participant to participate or potentially confound the study results.

2. If female, the participant is pregnant or lactating or intending to become pregnant, or intending to donate ova, before, during the course of the study or within 12 weeks after last dose.

3. Intends to donate sperm during the course of this study or for 12 weeks after last dose.

4. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking TAK-063, or a similar drug in the same class, or that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias.

Healthy Participants:

1. Has a history or treatment of Axis I/II mental disorders according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) such as depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, anorexia nervosa, bulimia nervosa or schizophrenia within the past 3 years.

2. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in Day -1. Cotinine test is positive at Screening or Check-in (Day -1).

Participants with Stable Schizophrenia:

1. Has a history of a primary DSM-IV axis I diagnosis other than schizophrenia or schizoaffective disorder.

2. Has not discontinued antipsychotic or other psychotropic medications or is unable to discontinue antipsychotic or other psychotropic medications at Day -7 (or five half-lives prior to Day -1).

3. Is taking a concomitant medication for a medical condition at a stable dose or regimen for less than two months or is taking a concomitant medication for a medical condition for less than two months and for which the discontinuation for the study period is not medically permissible.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• TAK-063
TAK-063 tablets
• TAK-063 Placebo
TAK-063 placebo-matching tablets

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) after 7 days of dosing	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.; An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.	Day 1 to Day 14	Yes
Primary	Percentage of participants with markedly abnormal safety laboratory tests	The percentage of participants with any markedly abnormal standard safety laboratory values, including hematology, serum chemistries, and urinalysis, during the treatment period.	Day 1 to Day 8	Yes
Primary	Percentage of participants with markedly abnormal vital sign measurements	The percentage of participants who meet markedly abnormal criteria for vital signs, including oral body temperature, respiration rate, pulse, and resting blood pressure and after standing	Day 1 to Day 8	Yes
Primary	Percentage of participants with markedly abnormal criteria for safety electrocardiogram (ECG) parameters	The percentage of participants who meet markedly abnormal criteria specified by the protocol and statistical analysis plan during the treatment period	Day 1 to Day 8	Yes
Secondary	Cmax: Maximum Observed Plasma Concentration for TAK-063 and TAK-063 metabolite M-I	Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.	Days 1 and 7	No
Secondary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-063 and TAK-063 metabolite M-I	Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.	Days 1 and 7	No
Secondary	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-063 and TAK-063 metabolite M-I	AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the Last Quantifiable Concentration.	Days 1 and 7	No
Secondary	AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose	AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose.	Days 1 and 7	No
Secondary	Ae(0-24): Total Amount Excreted in the Urine from Time 0 to 24 hours Postdose for TAK-063 and TAK-063 Metabolite M-I	Ae(0-24) is a measure of the total amount of study drug excreted in the urine from time 0 to 24 hours postdose.	Days 1 and 7	No
Secondary	Fe: Fraction of Drug Excreted in Urine for TAK-063	Fe is a measure of the fraction of drug excreted in urine and is calculated as Fe = (total amount excreted in the urine from time 0 to 24 hours post-dose / dose)×100	Days 1 and 7	No
Secondary	CLr: Renal Clearance of TAK-063 and TAK-063 metabolite M-I	CLr is a measure of apparent clearance of the drug from the urine calculated as total amount excreted in the urine from time 0 to 24 hours postdose / plasma area under the curve from time 0 to 24 hours post-dose.	Days 1 and 7	No
Secondary	CL/F: Oral Clearance of TAK-063	CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by area under the curve from time 0 to 24 hours post-dose, after multiple dosing (at steady state).	Day 7	No
Secondary	Average Plasma Concentration on Day 1 (Cav) and Day 7 (Cavss) for TAK-063 and TAK-063 metabolite M-I	Cav is the Average plasma concentration on Day 1, calculated as AUC(0-24)/24. Cavss is the average plasma concentration on Day 7, calculated as AUC(0-24)/24.	Days 1 and 7	No
Secondary	Ratio of TAK-063 Metabolite Cmax to TAK-063 Cmax	Cmax Ratio is the ratio of Cmax values of the metabolite compared to the parent calculated by dividing Cmax values of metabolite M-I with those of the parent drug TAK-063.	Days 1 and 7 predose	No
Secondary	Accumulation ratios between Day 7 AUC(0-24) and Day 1 AUC(0-24)	Accumulation ratios between Day 7 AUC(0-24) and Day 1 AUC(0-24)	Days 1 and 7	No
Secondary	Ratio of TAK-063 Metabolite M-I AUC to TAK-063 AUC	AUC Ratio is the ratio of AUC values of the metabolite compared to the parent calculated by dividing AUC values of metabolite M-I with those of the parent drug TAK-063.	Days 1 and 7	No